Aktienanalyse zu Zura Bio Ltd (ZURA)ZURAZura Bio Ltd

Zura Bio Limited is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies. It is developing a portfolio of therapeutic indications for tibulizumab (ZB-106), crebankitug (ZB-168), and torudokimab (ZB-880) with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases, including systemic sclerosis and other indications with unmet needs. ZB-106 is an immunoglobulin G single-chain variable fragment bispecific dual-antagonist antibody engineered by the fusion of TALTZ and tabalumab that neutralize interleukin-17A (IL-17A) and BAFF. ZB-168 is a fully human, high affinity monoclonal antibody that binds and neutralizes the IL-7 receptor chain alpha chain. ZB-880 is a fully human, high affinity monoclonal antibody that neutralizes IL-33, preventing ST2-dependent and ST2-independent inflammation. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Zura Bio Ltd is not a good buy right now due to its current price of $4, which is significantly below analyst price targets of $20 and $22. The RSI is at 36.046, indicating that the stock is nearing oversold territory, but the negative trend in net income, with a loss of $26.3 million reported in Q2 2026, raises concerns about its financial stability. The main risk is the high insider selling and a short interest of 15.95%, reflecting skepticism about future performance.